

**Site Agreement**  
**Participation in Retrospective Healthcare Research Project (the "Agreement")**

Between

TriNetX Oncology GmbH, with address at Heinrich-von-Stephan-Straße 5, 79100 Freiburg, Germany and represented by its Managing Director, Andreas Weber ("TNXO").

And \_\_\_\_\_ (SITE Name)

with address at \_\_\_\_\_  
(SITE Address)

and represented by \_\_\_\_\_ (SITE Representative)  
("SITE").

**Contact details project conduct**

SITE contact information for TNXO queries regarding documentation (can be the same as SITE Representative):

\_\_\_\_\_  
(Name)

\_\_\_\_\_  
(Email address)

\_\_\_\_\_  
(Phone number)

**§ 1 Subject matter of the contract**

SITE hereby agrees to participate in a TNXO retrospective healthcare research project entitled, "**Feasibility Study prior to an External Control Arm Study (ECA) on Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Europe**" (the "Study"), in accordance with the Study description set forth in Exhibit A.

The SITE hereby agrees to which module it would like to participate in:

- Feasibility survey (Module 1)
- External Control Arm (Module 2)

By entering into this Agreement, the Site acknowledges having reviewed and accepted the TriNetX Oncology Site Contracts Agreement Terms & Conditions accessible at <https://www2.trinetx.com/oncology-site-contracts-agreement-terms-conditions> which are incorporated herein and form an integral part of this Agreement.

**§2 Duration**

This Agreement commences as of May 5, 2026 ("**Effective Date**") and continues until the later of (i) June 30, 2026, or (ii) completion of the Study ("**Term**"). Each party may terminate this Agreement for any reason upon 30 days prior written notice to the other party.

### § 3 Remuneration

SITE shall receive a fee for each complete retrospective anonymized documentation of a course of therapy or for each fully completed questionnaire within the period specified in Exhibit A. TNXO will arrange the payment promptly after the end of the project once the data has been quality assured.

- Feasibility survey (Module 1)
  - The fully completed questionnaire will be rewarded with €800 (plus VAT if applicable).
- External Control Arm (Module 2)
  - Each fully documented eligible patient on the third line of treatment: €400 (plus VAT if applicable).
  - Each fully documented eligible patient on the fourth line of treatment: €450 (plus VAT if applicable).
  - Each fully documented eligible patient on the fifth line of treatment or a subsequent line: €500 (plus VAT if applicable).

SITE provides below its bank information for TNXO to complete the transfer properly:

<i>Bank Details of the Recipient</i>	
<b>Recipient Account Name</b>	
<b>Currency</b>	€
<b>IBAN</b>	
<b>Swift/BIC Code (required for all international transfers)</b>	
<b>Billing email</b>	
<b>Tax No. or VAT ID</b>	

### §4 GOVERNING LAW; JURISDICTION

This Agreement shall be interpreted and governed by the laws of Germany. The place of jurisdiction is Freiburg, Germany.

**SIGNATURES**

By executing this Agreement, the Site warrants that all approvals required for the Site and its representatives to perform the Study have been duly obtained from the facility where they are engaged.

**TriNetX Oncology GmbH**

**SITE**

Signature: \_\_\_\_\_

Signature: \_\_\_\_\_

Name: Andreas Weber

Name: \_\_\_\_\_

Title: Managing Director

Title: \_\_\_\_\_

Date: \_\_\_\_\_

Date: \_\_\_\_\_

**EXHIBIT A**  
**(Study Description)**

The Site confirms receipt of the Study Description, which was transmitted to it by email, and acknowledges that an electronic copy is accessible via the following link: [https://oncology.trinetx.com/wp-content/uploads/sites/26/2026/04/2026-04-24\\_Synopsis\\_ECA\\_DLCL\\_ENG\\_2025.pdf](https://oncology.trinetx.com/wp-content/uploads/sites/26/2026/04/2026-04-24_Synopsis_ECA_DLCL_ENG_2025.pdf)